2. Academic Validation
  3. Discovery, structure-activity relationship study, and oral analgesic efficacy of cyproheptadine derivatives possessing N-type calcium channel inhibitory activity

Discovery, structure-activity relationship study, and oral analgesic efficacy of cyproheptadine derivatives possessing N-type calcium channel inhibitory activity

  • Bioorg Med Chem. 2006 Aug 1;14(15):5333-9. doi: 10.1016/j.bmc.2006.03.040.
Takashi Yamamoto 1,  Seiji Niwa,  Satoshi Iwayama,  Hajime Koganei,  Shin-ichi Fujita,  Tomoko Takeda,  Morikazu Kito,  Yukitsugu Ono,  Yuki Saitou,  Akira Takahara,  Seinosuke Iwata,  Hiroshi Yamamoto,  Masataka Shoji
Affiliations

Affiliation

  • 1 Pharmaceutical Research Laboratory, Ajinomoto company Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Japan.
PMID: 16616501 DOI: 10.1016/j.bmc.2006.03.040
Abstract

Antiallergic drug cyproheptadine (Cyp) is known to have inhibitory activities for L-type calcium channels in addition to histamine and serotonin receptors. Since we found that Cyp had an inhibitory activity against N-type Calcium Channel, Cyp was optimized to obtain more selective N-type Calcium Channel blocker with analgesic action. As a consequence of the optimization, we found 13 with potent N-type Calcium Channel inhibitory activity which had lower inhibitory activities against L-type Calcium Channel, histamine (H1), and serotonin (5-HT2A) receptors than those of Cyp. 13 showed an oral analgesic activity in rat formalin-induced pain model.

Figures
Products